Evidence map›Paper›PMID 40080633›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025

Circulating CD34-positive cells are associated with prolonged time to fracture in people with Duchenne muscular dystrophy on chronic glucocorticoids.

Angela Sadlowski, Julia See, Sonum Bharill, Weixin Zhang, Arryn Otte, Emely Loscalzo, Nazanin Yousefzadeh, Ethan Gough, Tricia Nilles, Sisir Barik and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Angela SadlowskiDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Julia SeeDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Sonum BharillDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.ORCID 0000-0003-2933-5579
Weixin ZhangDepartment of Orthopedic Surgery, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Arryn OtteDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Emely LoscalzoDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Nazanin YousefzadehDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Ethan GoughDepartment of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 2128, United States.
Tricia NillesDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 2128, United States.
Sisir BarikDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Malinda WuDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.
Janet L CraneDepartment of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 2128, United States.ORCID 0000-0001-7713-0936

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Role of glucocorticoid-suppression of preosteoclast PDGF-BB in skeletal angiogenesisR01AR078793 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CRANE, JANET · 2021 to 2025
$1.8M
Angiogenic Potential in Children with Glucocorticoid-Induced OsteoporosisR03AR073939 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CRANE, JANET · 2018 to 2019
$164k
National Institute of Health 1R03AR073939National Institute of Health R01AR078793NIAID NIH HHS P30 AI094189NIAMS NIH HHS R01 AR078793NIAMS NIH HHS R03 AR073939
6 · The paper itself

Abstract

Glucocorticoids decrease preosteoclast (POC) platelet-derived-growth-factor-type-BB (PDGF-BB), reducing migration of endothelial and osteo-progenitor cells, impairing skeletal angiogenesis and osteogenesis in mice. To explore human translation, we conducted a case-control study on Duchenne muscular dystrophy (DMD) youth treated with chronic glucocorticoids (n=24) relative to healthy controls (n=13) to explore the association of PDGF-BB, VEGF, angiogenin concentration and peripheral blood mononuclear cell (PBMC) subpopulations as surrogates of POCs (CD14+/Stro-1-/CD105-), skeletal progenitor cells (SPCs: Stro-1+/CD105+/CD14-/CD45-), and endothelial/hematopoietic progenitor cells (CD34+/CD14-/Stro-1-/CD105-) and CE140b mean fluorescence intensity (MFI) to fracture. People with DMD (8-20 years), were stratified by prior and subsequent fractures relative to biospecimen collection. Healthy controls were age- and sex-matched. Differences between groups were assessed with one-way ANOVA with post-hoc Tukey's test, retrospective fractures by Kendall Tau correlation, and prospective fractures by bivariable and multivariable accelerated time failure models. Baseline characteristics between groups were similar, though people with DMD were shorter relative to healthy controls, and in the DMD groups, those with prior fractures had a longer duration of glucocorticoid therapy. We noted decreased PDGF-BB concentration and percentages of circulating POCs, SPCs, and CD34+ cells in people with DMD relative to healthy controls. Circulating CD34+ cell percentage positively correlated with PDGF-BB concentration, similar to murine models. Lower percentage of circulating SPCs and CD140b MFI was associated with increased number of retrospective fractures. After a mean follow-up of 2.23 yr, 79% of people with DMD sustained a subsequent fracture. Higher PDGF-BB concentration and percent of POC, SPCs, and CD34+ cells were associated with a longer time to next fracture. After controlling for covariates of fracture risk, increased percentage of CD34+ cells continued to be associated with prolonged time to fracture. Circulating CD34+ cells may thus be a potential biomarker to predict acute fracture risk in young people with DMD on chronic glucocorticoids.

Indexed as

Antigens, CD34Fractures, BoneGlucocorticoidsMuscular Dystrophy, DuchenneAdolescentAdultCase-Control StudiesChildFemaleHumansMaleTime FactorsYoung AdultAntigens, CD34GlucocorticoidsbiomarkerDuchenne muscular dystrophyendothelial cellsosteoporosisplatelet-derived-growth-factor-type-BB

Identifiers

PMID40080633
PMCPMC12103721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.